Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Surgery, Tissue Plasminogen Activator, Antiangiogenic Agents and Age Related Macular Degeneration Complications (STAR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02557451
Recruitment Status : Unknown
Verified January 2018 by Centre Hospitalier Universitaire Dijon.
Recruitment status was:  Recruiting
First Posted : September 23, 2015
Last Update Posted : February 1, 2018
Sponsor:
Information provided by (Responsible Party):
Centre Hospitalier Universitaire Dijon

Brief Summary:

AMD is a disease of the central retina, a zone that enables fine detail activities (reading, detail…). This central zone of the retina can be affected by a haemorrhagic complication when small abnormal vessels suddenly start to bleed inside the retina. Several therapeutic approaches are currently available even though they have never been truly compared. The study will be proposed to patients who need to be treated for haemorrhage of the macula. A certain number of factors will be evaluated to compare the 2 principal approaches currently used in France: surgery followed by injections of an anti-angiogenic OR intravitreal injections of gas followed by injections of anti-angiogenics. This is a multicentre, randomized controlled trial to compare these 2 therapeutic approaches.

These diametrically opposed approaches have very different consequences for patients and in terms of cost for society. The consequences for patients will be immediately measurable so as to determine the best therapeutic approach in terms of functional recovery and the impact of the disease on quality of life, while taking into account the risks inherent to these 2 treatments. The impact on quality of life of these 2 approaches as well as their consequences - an important factor in this disease, which is a cause of sensory handicap - will provide the ophthalmological community with essential information making it possible to validate one or the other of these methods for the management of these haematomas.


Condition or disease Intervention/treatment Phase
Subretinal Haematoma Linked to AMD Other: Surgery Other: Intravitreal injections of gas Procedure: injections of an antiangiogenic Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 90 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Official Title: Subretinal Haematoma in AMD: Randomized Controlled Study of 2 Therapeutic Approaches in the Antiangiogenic Era
Actual Study Start Date : April 28, 2016
Estimated Primary Completion Date : January 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: surgery + antiangiogenic
surgery (vitrectomy - air - TPA) with injections of an antiangiogenic
Other: Surgery
Procedure: injections of an antiangiogenic
Experimental: intravitreal injection of gas/TPA + antiangiogenic
intravitreal injection of gas - TPA with injections of an antiangiogenic
Other: Intravitreal injections of gas
Procedure: injections of an antiangiogenic



Primary Outcome Measures :
  1. Visual acuity measured on the ETDRS scale [ Time Frame: Change from inclusion at 3 months ]

Secondary Outcome Measures :
  1. Visual acuity measured on the ETDRS scale [ Time Frame: At 1 month and 6 months ]
  2. Area of the scotoma presented by the patient according to the Amsler grid [ Time Frame: At 1 month, 3 months and 6 months ]
  3. Quality of life using the VFQ-25 scale [ Time Frame: At 3 months and 6 months ]
  4. Number of injections of an antiangiogenic at the end of the 6 months of treatment [ Time Frame: At 6 months ]
  5. Number of patients with macular bleeding [ Time Frame: At 6 months ]
  6. Area of hypoautofluorescence using the autofluorescence technique [ Time Frame: At 3 and 6 months ]
  7. Complications rate [ Time Frame: At 6 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:

Patients presenting subretinal haematoma linked to AMD

  • Occurring at least14 days before the start of therapy
  • With the presence of a component overlying the pigmentary epithelium (PE) on the OCT
  • And a diameter greater than two pupillary diameters on the retinal photographs

Patients who have provided oral consent

Patients with National Health Insurance cover

Patients available for monthly follow-up

Patient having an effective contraception for the women old enough to procreate during the treatment and during 6 months which follow his stop.

Exclusion Criteria:

  • Subretinal haematoma linked to a cause other than AMD (myopia, angioid streaks…)
  • History of subretinal haematoma on the same side
  • Cloudy humour making it impossible to photograph the fundus of the eye or carry out angiography
  • Component of the haematoma exclusively underlying the pigmentry epithelium
  • Haemorrhage without lifting of the retina
  • Patients presenting an INR greater than 4, thus contra-indicating surgery
  • Patients requiring cataract surgery in the first 3 months of the study
  • Patients presenting a contra-indication relative to injection of the antiangiogenic (History of AVC bleeding or unknown origin in the last 6 months or MI in the 3 preceding months)
  • Pregnant or breast-feeding woman (the patients do not have to breast-feed during at least 6 months after the administration of the last dose of the antiangiogénique)
  • Contraindication in the use of ranibizumab: hypersensitivity in the active ingredient or in one of the excipients, eye infection or périoculaire active or suspected, inflammation intraoculaire active severe, treatments anti-VEGF systematic or eye concomitant,
  • Contraindication in the use of bevacizumab: hypersensitivity in the active substance or in one of the excipients, the hypersensitivity in the products of the ovarian cells of Chinese hamster (CHO) or in other antibodies human or humanized recombinants, heavy surgical operation dating less than 28 days, not totally healed surgical wound, history of lung bleeding or hémoptysie
  • Contraindication in the use of alteplase: hypersensitivity in the active substance, in the gentamicine (a residue of the present manufacturing process in the state of tracks), or in one of the excipients. As all the thrombolytic agents, contraindication in every case associated to a high hemorrhagic risk (current significant hemorrhagic disorder or during the last six months, hemorrhagic known diathesis, concomitant treatment by oral anticoagulants with effective dose, severe or potentially dangerous, obvious or recent bleeding, histories or suspicion of intra-cranial bleeding, suspicion of sub-arachnoid bleeding or history of sub-arachnoid bleeding bound to an aneurysm, histories of severe lesion of the central nervous system (for example néoplasie, aneurysm, surgical operation intracerebral or intrathecal), recent traumatic external cardiac massage (less than 10 days), delivery, recent draining of a vessel not accessible to the compression (for example draining of the subclavian or jugular vein),severe uncontrolled high blood pressure, bacterial endocarditis, pericarditis, acute pancreatitis, gastrointestinal ulcers documented during the last 3 months, esophageal varices, arterial aneurysm, arterial or venous deformations, neoplasia increasing the hemorrhagic risk, severe hepatic disease, including hepatic insufficiency, cirrhosis, portal hypertension (esophageal varicose veins) and evolutionary hepatitis, surgical operation or important traumas during the last 3 months.
  • Contraindication in the use of acetazolamide: hypersensitivity in the acetazolamide or in one of excipients, severe hepatic, renal or suprarenal inadequacies, intolerance in sulphonamide, histories of renal colic, allergy in the wheat (other than the coeliac disease).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02557451


Contacts
Layout table for location contacts
Contact: Alain BRON 3 80 29 51 73 ext +33 alain.bron@chu-dijon.fr

Locations
Show Show 17 study locations
Sponsors and Collaborators
Centre Hospitalier Universitaire Dijon
Layout table for additonal information
Responsible Party: Centre Hospitalier Universitaire Dijon
ClinicalTrials.gov Identifier: NCT02557451    
Other Study ID Numbers: BRON PHRC I 2013
First Posted: September 23, 2015    Key Record Dates
Last Update Posted: February 1, 2018
Last Verified: January 2018
Additional relevant MeSH terms:
Layout table for MeSH terms
Hematoma
Hemorrhage
Pathologic Processes
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents